Cariprazine free base
new
featured

    WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 330051

CAS#: 839712-12-8 (free base)

Description: Cariprazine, also known as RGH-188 and MP-214, is an antipsychotic drug received FDA approval on September 17, 2015. Cariprazine acts as a D2 and D3 receptor partial agonist, with high selectivity towards the D3 receptor. Action on the dopaminergic systems makes it also potentially useful as an add-on therapy in major depressive disorder. Cariprazine is approved for schizophrenia and bipolar disorder. It has also been investigated as a potential adjunct in treatment-resistant major depressive disorder.


Chemical Structure

img
Cariprazine free base
CAS# 839712-12-8 (free base)

Theoretical Analysis

MedKoo Cat#: 330051
Name: Cariprazine free base
CAS#: 839712-12-8 (free base)
Chemical Formula: C21H32Cl2N4O
Exact Mass: 426.1953
Molecular Weight: 427.414
Elemental Analysis: C, 59.01; H, 7.55; Cl, 16.59; N, 13.11; O, 3.74

Price and Availability

Size Price Availability Quantity
50.0mg USD 150.0 2 Weeks
100.0mg USD 250.0 2 Weeks
200.0mg USD 450.0 2 Weeks
500.0mg USD 950.0 2 Weeks
1.0g USD 1650.0 2 Weeks
2.0g USD 2950.0 2 Weeks
5.0g USD 5850.0 2 Weeks
10.0g USD 8950.0 2 Weeks
Click to view more sizes and prices
Bulk inquiry

Related CAS #: 1083076-69-0 (HCl)   839712-12-8 (free base)  

Synonym: Cariprazine free base; RGH-188; RGH188; RGH 188; MP-214; MP 214; MP214;

IUPAC/Chemical Name: 3-((1r,4r)-4-(2-(4-(2,3-dichlorophenyl)piperazin-1-yl)ethyl)cyclohexyl)-1,1-dimethylurea

InChi Key: KPWSJANDNDDRMB-QAQDUYKDSA-N

InChi Code: InChI=1S/C21H32Cl2N4O/c1-25(2)21(28)24-17-8-6-16(7-9-17)10-11-26-12-14-27(15-13-26)19-5-3-4-18(22)20(19)23/h3-5,16-17H,6-15H2,1-2H3,(H,24,28)/t16-,17-

SMILES Code: O=C(N[C@H]1CC[C@H](CCN2CCN(C3=CC=CC(Cl)=C3Cl)CC2)CC1)N(C)C

Appearance: Solid powder

Purity: >98% (or refer to the Certificate of Analysis)

Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility: Soluble in DMSO

Shelf Life: >3 years if stored properly

Drug Formulation: This drug may be formulated in DMSO

Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code: 2934.99.9001

Preparing Stock Solutions

The following data is based on the product molecular weight 427.414 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL

Molarity Calculator

Calculate the mass, volume, or concentration required for a solution.
=
x
x
g/mol

*When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and SDS / CoA (available online).

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.

=
÷

Dilution Calculator

Calculate the dilution required to prepare a stock solution.
x
=
x

1: Rolin D, Whelan J, Montano CB. Is it depression or is it bipolar depression? J Am Assoc Nurse Pract. 2020 Oct;32(10):703-713. doi: 10.1097/JXX.0000000000000499. PMID: 33017361.

2: Edinoff A, Ruoff MT, Ghaffar YT, Rezayev A, Jani D, Kaye AM, Cornett EM, Kaye AD, Viswanath O, Urits I. Cariprazine to Treat Schizophrenia and Bipolar Disorder in Adults. Psychopharmacol Bull. 2020 Sep 14;50(4):83-117. PMID: 33012874; PMCID: PMC7511151.

3: Fagiolini A, Alcalá JÁ, Aubel T, Bienkiewicz W, Bogren MMK, Gago J, Cerveri G, Colla M, Sanchez FC, Cuomo A, Helge F, Iacoponi E, Karlsson PA, Peddu P, Pettorruso M, Pereira HJR, Schölin JS, Vernaleken IB. Treating schizophrenia with cariprazine: from clinical research to clinical practice. Real world experiences and recommendations from an International Panel. Ann Gen Psychiatry. 2020 Sep 26;19:55. doi: 10.1186/s12991-020-00305-3. PMID: 32999683; PMCID: PMC7520022.

4: Dieci M, Trama A, Mansi G. Resolution of Citalopram Sexual Adverse Effects With Low Dose of Cariprazine: A Case Report. Clin Neuropharmacol. 2020 Sep/Oct;43(5):164-165. doi: 10.1097/WNF.0000000000000409. PMID: 32947429.

5: Yatham LN, Vieta E, McIntyre RS, Jain R, Patel M, Earley W. Broad Efficacy of Cariprazine on Depressive Symptoms in Bipolar Disorder and the Clinical Implications. Prim Care Companion CNS Disord. 2020 Sep 17;22(5):20m02611. doi: 10.4088/PCC.20m02611. PMID: 32942346.

6: Cernea S, Dima L, Correll CU, Manu P. Pharmacological Management of Glucose Dysregulation in Patients Treated with Second-Generation Antipsychotics. Drugs. 2020 Sep 15. doi: 10.1007/s40265-020-01393-x. Epub ahead of print. PMID: 32930957.

7: Vokó Z, Bitter I, Mersich B, Réthelyi J, Molnár A, Pitter JG, Götze Á, Horváth M, Kóczián K, Fonticoli L, Lelli F, Németh B. Using informative prior based on expert opinion in Bayesian estimation of the transition probability matrix in Markov modelling-an example from the cost-effectiveness analysis of the treatment of patients with predominantly negative symptoms of schizophrenia with cariprazine. Cost Eff Resour Alloc. 2020 Aug 27;18:28. doi: 10.1186/s12962-020-00224-w. PMID: 32874137; PMCID: PMC7457290.

8: Jimoh IJ, Sebe B, Balicza P, Fedor M, Pataky I, Rudas G, Gal A, Inczedy- Farkas G, Nemeth G, Molnar MJ. Wernicke-Korsakoff syndrome associated with mtDNA disease. Ther Adv Neurol Disord. 2020 Jul 30;13:1756286420938972. doi: 10.1177/1756286420938972. PMID: 32821290; PMCID: PMC7412926.

9: Roza TH, Santos Lopes SL, Passos IC. Cariprazine for acute mood episodes in bipolar disorder. Bipolar Disord. 2020 Aug 13. doi: 10.1111/bdi.12979. Epub ahead of print. PMID: 32790141.

10: Lumateperone (Caplyta) for schizophrenia. Med Lett Drugs Ther. 2020 Jul 27;62(1603):113-116. PMID: 32728011.

11: El Mansari M, Ebrahimzadeh M, Hamati R, Iro CM, Farkas B, Kiss B, Adham N, Blier P. Long-term administration of cariprazine increases locus coeruleus noradrenergic neurons activity and serotonin1A receptor neurotransmission in the hippocampus. J Psychopharmacol. 2020 Oct;34(10):1143-1154. doi: 10.1177/0269881120936891. Epub 2020 Jul 20. PMID: 32684081.

12: Orsolini L, De Berardis D, Volpe U. Up-to-date expert opinion on the safety of recently developed antipsychotics. Expert Opin Drug Saf. 2020 Aug;19(8):981-998. doi: 10.1080/14740338.2020.1795126. Epub 2020 Jul 21. PMID: 32657173.

13: Yalin N, Young AH. Pharmacological Treatment of Bipolar Depression: What are the Current and Emerging Options? Neuropsychiatr Dis Treat. 2020 Jun 9;16:1459-1472. doi: 10.2147/NDT.S245166. PMID: 32606699; PMCID: PMC7294105.

14: Grant JE, Chamberlain SR. Cariprazine treatment of borderline personality disorder: A case report. Psychiatry Clin Neurosci. 2020 Jun 26. doi: 10.1111/pcn.13094. Epub ahead of print. PMID: 32588527.

15: Genaro-Mattos TC, Anderson A, Allen LB, Tallman KA, Porter NA, Korade Z, Mirnics K. Maternal cariprazine exposure inhibits embryonic and postnatal brain cholesterol biosynthesis. Mol Psychiatry. 2020 Jun 5. doi: 10.1038/s41380-020-0801-x. Epub ahead of print. PMID: 32504050.

16: Molnar MJ, Jimoh IJ, Zeke H, Palásti Á, Fedor M. Early-Onset Schizophrenia With Predominantly Negative Symptoms: A Case Study of a Drug-Naive Female Patient Treated With Cariprazine. Front Pharmacol. 2020 Apr 23;11:477. doi: 10.3389/fphar.2020.00477. PMID: 32390838; PMCID: PMC7191004.

17: Bahji A, Ermacora D, Stephenson C, Hawken ER, Vazquez G. Comparative efficacy and tolerability of pharmacological treatments for the treatment of acute bipolar depression: A systematic review and network meta-analysis. J Affect Disord. 2020 May 15;269:154-184. doi: 10.1016/j.jad.2020.03.030. Epub 2020 Mar 20. PMID: 32339131.

18: Vita A, Ceraso A, Valsecchi P. Esperienze di switch a cariprazina in pazienti affetti da schizofrenia con ricorrenze. Riv Psichiatr. 2019 Nov- Dec;54(6):16-19. doi: 10.1708/3340.33098. PMID: 32310935.

19: Mencacci C, Cerveri G, Palazzo C, Gesi C, Salvi V. Esperienze di switch a cariprazina in pazienti affetti da schizofrenia con risposta parziale. Riv Psichiatr. 2019 Nov-Dec;54(6):11-15. doi: 10.1708/3340.33097. PMID: 32310934.

20: Amore M, Aguglia A. Esperienze di switch a cariprazina in pazienti schizofrenici con comparsa di effetti collaterali/comorbilità mediche. Riv Psichiatr. 2019 Nov-Dec;54(6):7-10. doi: 10.1708/3340.33096. PMID: 32310933.